Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 26;4(5):326–339. doi: 10.1002/acn3.413

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Survival analysis of Scn1a ^+/− mice. Survival curves comparing untreated and drug‐treated naïve (A, B) or hyperthermia‐primed (C) Scn1a ^+/− mice. Treatment began at P18 and survival was monitored until P30. (A) Carbamazepine, levetiracetam, and topiramate treatment (green lines) significantly improved survival compared to untreated naïve mice (n = 10–21 mice per treatment group). (B) Survival curves comparing untreated and lamotrigine‐treated Scn1a ^+/− mice. Treatment began at P18 and survival was monitored until P42 (n = 15–22 mice per treatment group). Lamotrigine treatment significantly improved survival compared to untreated mice (C) No difference in survival was identified in hyperthermia‐primed mice (n = 14–19 mice per treatment group). (*P < 0.05, Logrank Mantel‐Cox).